Business

Osisko Gold Royalties reports Q4 net income of $7.1 million, matching expectations. Adjusted earnings were 16 cents per share on revenue of $56.7 million. For the year, the company had a profit of $16.3 million, or 9 cents per share, on revenue of $191.2 million.

Published on: February 19, 2025, 11:06 PM UTC

Pan American Silver Q4 Earnings Meet Forecasts: PAAS reports net income of $107.8 million, revenue of $815.1 million in Q4 2022.

Published on: February 19, 2025, 11:06 PM UTC

Triple Flag Precious Metals reports Q4 profit of $41.3 million, beating expectations.

Published on: February 19, 2025, 11:06 PM UTC

Capstone Copper Corp. (CSFFF) reported fourth-quarter profit of $45.9 million, or 6 cents per share. Adjusted earnings were 4 cents per share. Revenue totaled $446.9 million. For the year, the company reported profit of $82.9 million, or 11 cents per share, on revenue of $1.6 billion.

Published on: February 19, 2025, 11:05 PM UTC

Nutrien Ltd.(NTR) reported fourth-quarter net income of $113 million, or 23 cents per share, missing Wall Street expectations. Revenue was $5.08 billion, also below estimates. For the year, the company reported profit of $674 million, or $1.36 per share, on revenue of $25.97 billion.

Published on: February 19, 2025, 11:05 PM UTC

CF Industries reports a 20% increase in Q4 profit driven by higher ammonia sales and steady prices, boosted by the acquisition of Waggaman ammonia production facility, leading to strong demand in North America and Brazil.

Published on: February 19, 2025, 11:04 PM UTC

Carvana beats on revenue and profit in Q4, but shares fall after hours as company cites 'significant growth' in 2025.

Published on: February 19, 2025, 11:02 PM UTC

Elon Musk's government efficiency commission, known as the DOGE commission, has released a list of alleged savings amounting to billions of dollars through canceled contracts and other measures. However, experts raise concerns about the accuracy of the reported savings, as some records show significant errors.

Published on: February 19, 2025, 11:02 PM UTC

BioMarin Pharmaceutical (NASDAQ: BMRN) reported strong Q4 results, beating analyst estimates for both revenue and EPS. The company's full-year revenue guidance came in above expectations, and its adjusted EPS guidance for the upcoming year is also above estimates. BioMarin's key takeaways for Q4 include revenue growth of 15.6% year-over-year, adjusted EPS of $0.92 vs. estimates of $0.74, revenue guidance of $3.15 billion, and adjusted EPS guidance of $4.30.

Published on: February 19, 2025, 10:11 PM UTC

CEO of Rio Tinto takes the unusual step to host earnings in Washington, DC, and meet with US legislators to understand the implications of President Trump's expanding trade war.

Published on: February 19, 2025, 10:10 PM UTC